Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: Use of biosimilar monoclonal antibodies in the clinic

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.19
Views: 189
Rating:

Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands

Prof Arnold Vulto speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the practicality and attitudes around the clinical use of biosimilar monoclonal antibodies from the perspective on an oncologist.

He explains that patients should not be further burdened with the discussions around biosimilar use.

Prof Vulto also addresses the issue of switching to a biosimilar from an originator product or from another biosimilar.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation